Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAA817

Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis Pharmaceuticals

Phase 3 Most advanced trial
NVS Developer

What is AAA817?

AAA817 is a radioligand therapy that binds PSMA on the surface of prostate cancer cells and emits radiation to kill them. It is being studied in PSMA-positive metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
[225Ac]Ac-PSMA-617
Drug type
Radiopharmaceutical
Targets
prostate-specific membrane antigen (PSMA) (FOLH1)
Mechanism
Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1)
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
AB6DQ43TKE

Conditions studied

Prostate Cancer

Other drugs acting on FOLH1

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind AAA817

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.